In a CD19/CD22 tandem-CAR trial in large B cell lymphoma and B-ALL (NCT03233854), CD19neg/low relapse was common, consistent with a selection pressure against CD19, whereas CD22 loss or decrease was not seen.213. This evidence concerns the gene CD22 and precursor B-cell acute lymphoblastic leukemia.